Skip to main content
Clinical Trials/NCT06335342
NCT06335342
Recruiting
Not Applicable

Radiotherapy Treatments for Neoplasms in the Head and Neck Region

European Institute of Oncology1 site in 1 country4,050 target enrollmentFebruary 22, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Neoplasms
Sponsor
European Institute of Oncology
Enrollment
4050
Locations
1
Primary Endpoint
Overall Survival
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The aim of this study is the evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of radiotherapy treatments in the head and neck region.

Eligible patients undergoing radiotherapy for primary or secondary neoplasms localized in the head and neck anatomical region.

Detailed Description

Approximately 60% of patients with neoplasms receive radiotherapy as part of their oncological treatment. Various primary tumors as well as metastases of various origins can be localized in the head and neck anatomical region. Patients with such neoplastic localizations will therefore receive radiotherapy treatment possibly associated with other systemic or surgical treatments. Treatment choice is usually established following multidisciplinary discussions, based on disease characteristics and stage, concurrent pathologies and pharmacological treatments, patient preferences, and functional aspects. The collection of data related to radiotherapy plays a crucial role in understanding various clinical aspects of the treatment itself. The availability of data from an increasing number of patients will allow the identification of clinical situations or technical parameters of radiotherapy correlated with treatment tolerance and effectiveness, aiming to identify the best treatment for these oncological pathologies. This project aims to collect data related to radiotherapy treatments for primary or secondary neoplasms of the head and neck region for scientific dissemination with the goal of establishing the basis for evaluating achieved results over time, and deriving from these elements useful for guiding the most effective treatment strategies and appropriate operational protocols.

Registry
clinicaltrials.gov
Start Date
February 22, 2018
End Date
December 31, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
European Institute of Oncology
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the head and neck region include those with:
  • Primary bone tumors,
  • Primary soft tissue tumors,
  • Primary tumors of the cardio-circulatory system,
  • Primary tumors of the lymphatic system,
  • Primary tumors of the nervous system and skin,
  • Secondary metastases from various origins localized in that district.
  • Signed informed consent

Exclusion Criteria

  • Radiotherapy in districts other than the head and neck region

Outcomes

Primary Outcomes

Overall Survival

Time Frame: 5 years

Number of patients death

Disease free survival

Time Frame: 5 years

Number of oncological event (local recurrence, distant metastasis, other primary tumor)

Study Sites (1)

Loading locations...

Similar Trials